(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau





(43) International Publication Date 12 September 2003 (12.09.2003)

PCT

(10) International Publication Number WO 03/074515 A1

- (51) International Patent Classification⁷: C07D 403/12, 401/14, 403/14, 405/14, 413/14, A61K 31/506, A61P 35/00
- (21) International Application Number: PCT/US03/06022
- (22) International Filing Date: 28 February 2003 (28.02.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/360,741

1 March 2002 (01.03.2002) US

- (71) Applicant (for all designated States except US):
 SMITHKLINE BEECHAM CORPORATION
 [US/US]; One Franklin Plaza, Philadelphia, , PA 19101
 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHAMBERLAIN, Stanley, Dawes [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). CHEUNG, Mui [CN/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). EMERSON, Holly, Kathleen [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). JOHNSON, Neil, W. [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). NAILOR, Kristen, Elizabeth [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398,

Research Triangle Park, NC 27709 (US). SAMMOND, Douglas, McCord [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). SEMONES, Marcus [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).


- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS



(57) Abstract: Benzimidazole derivatives of formula (I), which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases. (I)



PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| Applicant's or agent's file reference FOR FURTHER See Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. | | | | | | |
|--|--|--|--|--|--|--|
| International application No. | International filing date (day/month/year) | (Earliest) Priority Date (day/month/year) | | | | |
| PCT/US 03/06022 | 28/02/2003 | 01/03/2002 | | | | |
| Applicant SMITHKLINE BEECHAM CORPOR | ATION | | | | | |
| according to Article 18. A copy is being tr This International Search Report consists | - | | | | | |
| Basis of the report With regard to the language, the | international search was carried out on the ba | asis of the international application in the | | | | |
| a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item. the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)). b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. turnished subsequently to this Authority in computer readable form. the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished Certain claims were found unsearchable (See Box I). Unity of invention is lacking (see Box II). With regard to the title, the text is approved as submitted by the applicant. The text has been established by this Authority to read as follows: DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | | | | | | |
| the text has been estable | submitted by the applicant. ished, according to Rule 38.2(b), by this Autho ne date of mailing of this international search ro | ority as it appears in Box III. The applicant may, eport, sybmit comments to this Authority. | | | | |
| as suggested by the applicant fa | blished with the abstract is Figure No. plicant. ailed to suggest a figure. er characterizes the invention. | None of the figures. | | | | |

International application No.

PCT/US 03/06022

INTERNATIONAL SEARCH REPORT

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

Benzimidazole derivatives of formula (I), which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

. CLASSIFICATION OF SUBJECT MATTER PC 7 C07D403/12 C07U CO7D409/14 C07D403/14 C07D405/14 CO7D401/14 A61K31/506 A61P35/00 CO7D413/14 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category WO 97 19065 A (CELLTECH THERAPEUTICS 1 - 60Υ LIMITED) 29 May 1997 (1997-05-29) the whole document, particularly example 101 1 - 60WO 00 12089 A (MERCK & CO., INC.) 9 March 2000 (2000-03-09) the whole document 1 - 60WO 02 059110 A (GLAXO GROUP LIMITED) P,Y 1 August 2002 (2002-08-01) the whole document, particularly examples 74 and 75 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the 'A' document defining the general state of the art which is not considered to be of particular relevance invention *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the *O* document referring to an oral disclosure, use, exhibition or document is combined with one or more other such docu-ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 25/06/2003 6 June 2003 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Fax: (+31-70) 340-3016

Allard, M

International Application No. PCT/US 03 \(06022 \)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1, 2, 23-60 (all in part)

The scope of claims 1, 2 and 23-60, in as far as the expression "physiologically functional derivative" is concerned, is so unclear (Article 6 PCT) that a meaningful international search is impossible with regard to this expression.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



international application No. PCT/US 03/06022

| Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) | | | | | | |
|---|--|--|--|--|--|--|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | | | | |
| 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: | | | | | | |
| Although claims 34, 35, 39-59 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. | | | | | | |
| 2. X Claims Nos.: 1, 2, 23-60 (all in part) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: | | | | | | |
| see FURTHER INFORMATION sheet PCT/ISA/210 | | | | | | |
| Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). | | | | | | |
| Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) | | | | | | |
| This International Searching Authority found multiple inventions in this international application, as follows: | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. | | | | | | |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. | | | | | | |
| 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: | | | | | | |
| | | | | | | |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | | | | | | |
| | | | | | | |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. | | | | | | |
| No protest accompanied the payment of additional search fees. | | | | | | |

Information on patent family members

etional Application No PCT/US 03/06022

| Patent document cited in search report | Publication date | | Patent family member(s) | Publication date |
|--|------------------|----|----------------------------|------------------|
| WO 9719065 A | 29-05-1997 | AU | 7631496 A | 11-06-1997 |
| | | DE | 69627179 D | 1 08-05-2003 |
| | | EP | 0862560 A | 1 09-09-1998 |
| | | WO | 9719065 A | 1 29-05-1997 |
| | | US | 6235746 B | 1 22-05-2001 |
| | | US | 5958935 A | 28-09-1999 |
| WO 0012089 A | 09-03-2000 | AU | 3078999 A | 21-03-2000 |
| | | CA | 2341409 A | 1 09-03-2000 |
| | | EP | 1109555 A | 27-06-2001 |
| | | JP | 2002523459 T | 30-07-2002 |
| | | WO | 0012089 A | 1 09-03-2000 |
| | | US | 6162804 A | 19-12-2000 |
| | | US | 6465484 B | 15-10-2002 |
| WO 02059110 A | 01-08-2002 | WO | 02059110 A | 1 01-08-2002 |